STOCK TITAN
  1. Home
  2. Sec-filings
  3. IKT
  4. [Form 3] Inhibikase Therapeutics, Inc. Initial Statement of Beneficial Ownership

RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Inhibikase Therapeutics, Inc. has a major shareholder group associated with RA Capital reporting indirect ownership of 25,000,000 shares of common stock as of July 10, 2026.

The shares are held directly by RA Capital Healthcare Fund LP, with RA Capital Management as investment manager and its principals Dr. Peter Kolchinsky and Mr. Rajeev Shah as managing members, each disclaiming beneficial ownership beyond their pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner
Type Security Shares Price Value
holding Common Stock F1, F2 -- -- --
Holdings After Transaction: Common Stock — 25,000,000 shares (Indirect, See footnotes)
Footnotes (2)
  1. F1. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  2. F2. Held directly by the Fund.
Indirect common shares reported 25,000,000 shares Indirect holdings of common stock as of 2026-07-10
Holding entries reported 1 entry Non-transactional holding entry disclosed in this insider report
Reporting persons 4 filers RA Capital Management LP, RA Capital Healthcare Fund LP, Dr. Peter Kolchinsky, Mr. Rajeev Shah
ten percent owner regulatory
"Each reporting person is marked as a ten percent owner in the reporting persons section."
pecuniary interest financial
"Each party disclaims beneficial ownership except to the extent of its or his pecuniary interest."
indirect ownership financial
"The common stock holding is reported with ownership type coded as indirect."
investment manager financial
"RA Capital Management, L.P. is described as the investment manager for the Fund."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What stake in Inhibikase Therapeutics (IKT) does RA Capital report?
RA Capital–related entities report indirect ownership of 25,000,000 shares of Inhibikase Therapeutics common stock as of July 10, 2026, according to this insider ownership report filed for multiple affiliated reporting persons.

Who are the reporting persons in the Inhibikase Therapeutics (IKT) insider filing?
The filing lists RA Capital Management, L.P., RA Capital Healthcare Fund LP, Dr. Peter Kolchinsky, and Mr. Rajeev Shah as reporting persons, each identified as a ten percent owner of Inhibikase Therapeutics (IKT).

How is the Inhibikase Therapeutics (IKT) stake held according to the filing?
The reported Inhibikase (IKT) stake is held directly by RA Capital Healthcare Fund LP. RA Capital Management, L.P. acts as investment manager, and RA Capital Management GP, LLC is its general partner, with Dr. Kolchinsky and Mr. Shah as managing members.

Do the reporting persons claim full beneficial ownership of IKT shares?
No. Each of the Adviser, the Fund, the Adviser GP, Dr. Peter Kolchinsky, and Mr. Rajeev Shah disclaims beneficial ownership of the reported Inhibikase (IKT) securities except to the extent of its or his pecuniary interest.

Does this Inhibikase Therapeutics (IKT) Form 3 show recent share purchases or sales?
No. The filing reports a holding entry of 25,000,000 common shares held indirectly and does not list any purchase or sale transactions, transaction prices, or changes in the number of shares on the reported date.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
RA CAPITAL MANAGEMENT, L.P.
(Last)(First)(Middle)
200 BERKELEY STREET, 18TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
07/10/2026		3. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock25,000,000ISee footnotes(1)(2)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
RA CAPITAL MANAGEMENT, L.P.
(Last)(First)(Middle)
200 BERKELEY STREET, 18TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
RA Capital Healthcare Fund LP
(Last)(First)(Middle)
C/O RA CAPITAL MANAGEMENT, L.P.
200 BERKELEY STREET, 18TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Kolchinsky Peter
(Last)(First)(Middle)
C/O RA CAPITAL MANAGEMENT, L.P.
200 BERKELEY STREET, 18TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Shah Rajeev M.
(Last)(First)(Middle)
C/O RA CAPITAL MANAGEMENT, L.P.
200 BERKELEY STREET, 18TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
2. Held directly by the Fund.
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.07/17/2026
/s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.07/17/2026
/s/ Peter Kolchinsky, individually07/17/2026
/s/ Rajeev Shah, individually07/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR